2024 Cardio-Oncology and Amyloidosis Symposium

This conference has already taken place.

Cardio-oncology is an expanding field that has great importance as newly developed cancer treatments improve cancer survival. With new treatments come new or unexpected cardiovascular toxicities as many cancer survivors are now living long enough to experience the potential cardiotoxic effects of these treatments. Presentations will address: cardiotoxic effects of cancer therapies; strategies to recognize when cardiovascular issues develop in cancer patients and survivors; role of cardioprotective therapy in patients requiring cancer treatment(s); how to integrate recent cardio-oncology guidelines into clinical practice and identify recent advancements and challenges diagnosing and managing cardiac amyloidosis.

This meeting is endorsed by the International Cardio-Oncology Society (IC-OS.org). IC-OS exists to advance the quality of cardio-oncology care by collaborating among educators, researchers, clinicians, and allied health professionals from around the world.

THIS CONTINUING MEDICAL EDUCATION ACTIVITY IS AVAILABLE FOR IN-PERSON OR ONLINE PARTICIPATION

ONLINE REGISTRATION IS NOW CLOSED. FOR LATE REGISTRATION PHONE OR EMAIL THE CONTACT LISTED BELOW

• Additional Info
• Agenda
• Pricing
• Speakers
• Location
• Accreditation & Credit Statements

Dates and Times

Start: 6/1/2024 7:50 AM
End: 6/1/2024 4:05 PM

Objectives

At the conclusion of this activity, learners will be able to:
1. Define the short-term and long-term cardiotoxic effects of modern cancer therapies.
2. Define the best strategies to recognize when cardiovascular issues develop in your cancer patients and survivors.
3. Define the role of cardioprotective therapy in your patients requiring cancer treatment(s).
4. Compare cardiac imaging modalities to determine the best test in specific cancer scenarios.
5. Identify and integrate recent cardio-oncology guidelines into your clinical practice.
6. Identify recent advancements and challenges in diagnosing and managing cardiac amyloidosis.

Agenda

Pricing

Tier	Price
Physician, attending in person	$0.00
Physician. participating online	$0.00
Physician Assistant, attending in person	$0.00
Physician Assistant, participating online	$0.00
Resident/Fellow/Student, attending in person	$0.00
Resident/Fellow/Student, participating online	$0.00
Nurse/Nurse Practitioner, attending in person	$0.00
Nurse/Nurse Practitioner, participating online	$0.00
Allied Medical Professional, attending in person	$0.00
Allied Health Professional, participating online	$0.00
Other, attending in person	$0.00
Other, participating online	$0.00

Speakers

• Dr. Daniel Addison, MD
  • Overview – What is Cardio-Oncology in the Contemporary Era?
• Dr. Lauren Baldassarre, MD
  • Uses of Multimodality Cardiac Imaging in the Cancer Patient
• Dr. Marina Beltrami Moreira, MD
  • Clonal Hematopoiesis (CHIP) and the Risk of Cardiovascular Events
• Dr. Konstantinos Boudoulas, MD
  • Managing Acute Coronary Syndromes in Cancer Patients
• Dr. Jonathan Brammer, MD
  • Cardiotoxicity with Cellular (CAR-T cells) Therapies
• Dr. Zachary Braunstein, MD
  • Case Scenario (BTKI Associated Cardiotoxicity)
  • Case Scenario (CAR-T cell Cardiotoxicity)
• Dr. Avirup Guha, MBBS
  • Cardiovascular Toxicity Risk in Prostate Cancer Patients
  • Disparities in Cardio-Oncology Populations
• Dr. Richard Gumina, MD
  • Addressing Chronic CAD in the Cancer Patient
• Dr. Salim Hayek, MD
  • Keynote Lecture: Role of Biomarkers in Immunotherapy-Associated Cardiotoxicity
• Dr. Mahmoud Houmsse, MD
  • Cardiac Device and Ablation Use in the Cancer Patient
• Dr. Michelle Kittleson, MD
  • Modern Directions in Cardiac Amyloidosis
• Dr. Adam Potter, MD
  • Uses of STRAIN Imaging in Patients with Cancer
• Dr. Jason Prosek, MD
  • Managing Hypertension Associated with the Cancer Patient
• Dr. Bhuvaneswari Ramaswamy, MD
  • Cardio-Oncology Needs from the Perspective of an Oncologist
• Dr. Kerry Rogers, MD
  • BTKI-Associated Cardiac Arrhythmias and Hypertension
• Dr. Diego Sadler, MD
  • Building Effective Networks for Clinical Cardio-Oncology Care and Research
• Dr. Sneha Sharma, DO
  • Case Scenario (CHF Myeloma, and Orthopedic Associations)
  • Case Scenario (Indeterminate PYP Imaging and Course of Care)
• Dr. Sakima Smith, MD
  • Mechanisms of TKI Cardiac Toxicity
• Dr. Rituraj Upadhyay, MD
  • Identifying and Managing Radiation associated CVD
• Dr. Ajay Vallakati, MD
  • Heart Failure Medication Titration in Cardiac Amyloidosis
  • Managing Advance Heart Failure in Cancer Patients
• Dr. Youssef Youssef, MD
  • Case Scenario (BTE Cell Induced Cardiotoxicity)
  • Case Scenario (Immune Checkpoint Myocarditis)

Panels

• Cardiac Complications of Cancer Immune Therapies - Panel Discussion of Cases
  • Dr. Avirup Guha, MBBS
  • Dr. Salim Hayek, MD
  • Dr. Adam Potter, MD
  • Dr. Youssef Youssef, MD
• Cardiac Complications of Cancer Immune Therapies - Panel Discussion of Cases
  • Dr. Narendranath Epperla, MD
• Novel Targeted and Cellular Immune Therapy associated Cardiotoxicities - Panel Discussion
  • Dr. Daniel Addison, MD
  • Dr. Lauren Baldassarre, MD
  • Dr. Jonathan Brammer, MD
  • Dr. Zachary Braunstein, MD
  • Dr. Mahmoud Houmsse, MD
• Updates and Management of Cardiac Amyloidosis - Panel Discussion
  • Dr. Courtney Campbell, MD
  • Dr. Rami Kahwash, MD
  • Dr. Sneha Sharma, DO
  • Dr. Ajay Vallakati, MD

Location

The Ohio State University Biological Research Tower
460 W. 12th Avenue
Columbus, OH 43210

Accreditation Statement

The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Ohio State University designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit(s) ^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.